Published in J Clin Microbiol on July 01, 1996
Development of antigen detection assay for diagnosis of tuberculosis using sputum samples. J Clin Microbiol (2000) 1.45
Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe (2013) 1.26
Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Res (2009) 1.08
B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 0.97
Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med (2014) 0.80
A toolbox for tuberculosis (TB) diagnosis: an Indian multi-centric study (2006-2008); evaluation of serological assays based on PGL-Tb1 and ESAT-6/CFP10 antigens for TB diagnosis. PLoS One (2014) 0.76
Detection of lipoarabinomannan antibodies in patients with newly acquired tuberculosis and patients with relapse tuberculosis. J Clin Microbiol (1997) 0.76
Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies. Scand J Immunol (1976) 2.78
The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed (1994) 2.38
Detection of lipoarabinomannan as a diagnostic test for tuberculosis. J Clin Microbiol (1992) 2.09
Tuberculosis in the AIDS era. Clin Microbiol Rev (1995) 1.85
Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. J Biol Chem (1992) 1.52
Immunoglobulin G subclass responses to mycobacterial lipoarabinomannan in HIV-infected and non-infected patients with tuberculosis. Clin Exp Immunol (1993) 1.12
Serologic diagnosis of tuberculosis through assays of lipoarabinomannan antigen or antibody or lysozyme level. J Clin Microbiol (1993) 0.88
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature (1984) 3.71
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol (1985) 1.88
Immune response and vaccine efficiency. Vaccine (1998) 1.74
Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (1998) 1.59
A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS (2001) 1.56
Assessment of an Interferon-gamma release assay for the diagnosis of latent tuberculosis infection in haemodialysis patient. Swiss Med Wkly (2010) 1.50
Cerebrospinal fluid immunoglobulins and multiple sclerosis. Correspondence with magnetic resonance imaging and visually evoked potential changes. Arch Neurol (1989) 1.44
Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis (1998) 1.42
Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J Gastroenterol Hepatol (1998) 1.41
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med (2006) 1.38
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
HIV-1 viral load in blood, semen and saliva. AIDS (1997) 1.27
High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr (1999) 1.17
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS (1998) 1.12
Serological evidence of human granulocytic ehrlichiosis in Switzerland. Eur J Clin Microbiol Infect Dis (1998) 1.11
Supposed lamarckian inheritance of immunological tolerance. Nature (1981) 1.05
Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ (1999) 1.04
Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol (1991) 1.04
Astrocytes as antigen-presenting cells. Part II: Unlike H-2K-dependent cytotoxic T cells, H-2Ia-restricted T cells are only stimulated in the presence of interferon-gamma. J Neuroimmunol (1986) 0.97
Non-H-2 and H-2-linked immune response genes control the cytotoxic T-cell response to H-Y. Immunogenetics (1982) 0.95
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS (1998) 0.93
T cell clones with normal or defective O-galactosylation from a patient with permanent mixed-field polyagglutinability. Eur J Immunol (1992) 0.92
The endothelium--astrocyte immune control system of the brain. Springer Semin Immunopathol (1985) 0.92
Factors associated with changes in HIV shedding in semen. AIDS Res Hum Retroviruses (1998) 0.91
Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2000) 0.90
Prevalence of hepatitis C infection in Malawi and lack of association with sexually transmitted diseases. Eur J Epidemiol (2000) 0.89
Genetic analysis of the non-H-2-linked Ir genes controlling the cytotoxic T-cell response to H-Y in H-2d mice. Immunogenetics (1982) 0.89
Pregnancy, immunosuppression and reactivation of latent toxoplasmosis. J Perinat Med (1995) 0.89
Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study. Ann Neurol (1988) 0.88
Electrophysiological investigations in adoptively transferred experimental autoimmune encephalomyelitis in the Lewis rat. Brain (1989) 0.88
Immune reactivity of progeny of tetraparental male mice. Nature (1981) 0.88
Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS. J Med Virol (2001) 0.87
Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol (2007) 0.87
T cell approach to demyelinating diseases. Springer Semin Immunopathol (1985) 0.85
The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neurol (1990) 0.84
Shedding of HIV-1 in semen during primary infection. AIDS (1997) 0.84
Immune mechanisms in inflammatory polyneuropathy. Ann N Y Acad Sci (1988) 0.84
The role of macrophages in experimental autoimmune neuritis induced by a P2-specific T-cell line. Ann Neurol (1988) 0.83
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS (2000) 0.83
Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus. Vet Immunol Immunopathol (1992) 0.82
Specific haplotype preference in congenic F1 hybrid mice in the cytotoxic T cell response to the male specific antigen H-Y. J Immunol (1981) 0.82
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer (1991) 0.82
Further studies on supposed lamarckian inheritance of immunological tolerance. Nature (1982) 0.80
High proportion of gamma-delta T cell receptor positive T cells in bronchoalveolar lavage and peripheral blood of HIV-infected patients with Pneumocystis carinii pneumonias. Respiration (1993) 0.80
High seroprevalence of parvovirus B19 among patients infected with human immunodeficiency virus. Clin Infect Dis (1996) 0.79
Using a neural network to identify potential HLA-DR1 binding sites within proteins. J Mol Recognit (1993) 0.79
Suppression of P2-T cell line-mediated experimental autoimmune neuritis by interleukin-2 receptor targeted monoclonal antibody ART 18. Brain Res (1989) 0.78
Immunodeficiency after major trauma and selective surgery. Pediatr Infect Dis J (1988) 0.78
Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. Swiss Med Wkly (2004) 0.78
On the role of astrocytes in polyclonal T cell activation. J Neuroimmunol (1986) 0.78
[The prognostic value of different patterns of change in the CD4 lymphocyte counts in 420 symptom-free HIV-1-infected persons]. Dtsch Med Wochenschr (1993) 0.77
HIV transmission after suspension of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 0.77
Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Antivir Ther (1998) 0.77
Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines. Brain (1991) 0.76
A randomised prospective study to evaluate a rapid HIV-antibody assay in the management of cases of percutaneous exposure amongst health care workers. Swiss Med Wkly (2001) 0.76
Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells. Cancer Immunol Immunother (1993) 0.76
Sensitization to human immunodeficiency virus in seronegative exposed partners. J Infect Dis (2000) 0.75
Areas of sequence homology between several staphylococcal exotoxin "superantigens" and the HIV-1 pol protein. AIDS Res Hum Retroviruses (1992) 0.75
Probability of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.75
Nontransmission of HIV: a multifactorial phenomenon. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.75
[Disseminated mycobacteriosis with M. kansasii in a case of AIDS without HIV infection]. Schweiz Med Wochenschr (1997) 0.75
T lymphocyte lines in the study of autoimmune disease. Blut (1984) 0.75
Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. HIV Med (2001) 0.75
[Loss of 2 kidney grafts due to recurrence of type II membrano-proliferative glomerulonephritis]. Schweiz Med Wochenschr (1980) 0.75
[Imported dengue fever in Switzerland--serological evidence for a hitherto unexpectedly high prevalence]. Schweiz Med Wochenschr (1995) 0.75
[The Sézary syndrome]. Schweiz Med Wochenschr (1976) 0.75
Identification of Borrelia afzelii in a juxta-articular fibroid nodule from a human immunodeficiency virus-positive patient with acrodermatitis chronica atrophicans. Arch Dermatol (1995) 0.75
Adoptive transfer experimental autoimmune encephalomyelitis. Evidence for central nerve and spinal root dysfunction. Ann N Y Acad Sci (1988) 0.75
Condom semen samples for unlinked anonymous HIV testing. Lancet (1995) 0.75
An electronic study form to support collaborating agents in the management of clinical knowledge. Methods Inf Med (1999) 0.75
Conception of an XML-based ontology for a Web-based medical information service. Stud Health Technol Inform (2000) 0.75
Immune mechanisms in acute and chronic inflammatory polyneuropathies. J Neuroimmunol (1988) 0.75
[HIV serological parameters in the prognosis and follow-up assessment of an HIV infection]. Schweiz Med Wochenschr (1988) 0.75
[The natural history and laboratory parameters of HIV infection]. Dtsch Med Wochenschr (1989) 0.75
Recurrent brain abscesses in an HIV-positive patient with hereditary hemorrhagic telangiectasia and arteriovenous malformations of the lung. Eur J Clin Microbiol Infect Dis (1996) 0.75
[Cerebral toxoplasmosis with central diabetes insipidus and panhypopituitarism in a patient with AIDS]. Schweiz Med Wochenschr (1995) 0.75
Graduation of immunosuppression after surgery or severe trauma. Prog Clin Biol Res (1989) 0.75
[Immunologic changes and infection in severely injured patients]. Schweiz Med Wochenschr (1989) 0.75
The Sézary syndrome. Dermatologica (1979) 0.75
[The effect of rejection crises and immunosuppressive therapy on the lymphocyte subpopulations of patients after kidney transplantation]. Klin Wochenschr (1990) 0.75
Suppression of P2-T-cell line mediated experimental autoimmune neuritis by interleukin-2 receptor blockade. Ann N Y Acad Sci (1988) 0.75
[Immunosuppression caused by surgery and severe trauma]. Helv Chir Acta (1989) 0.75
T lymphocyte autoimmunity in experimental autoimmune encephalomyelitis. Concepts Immunopathol (1985) 0.75
[HIV prevention in HIV-positive drug addicts. A methadone-supported model]. Schweiz Med Wochenschr (1993) 0.75
Ciclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat. Neurosci Lett (1987) 0.75
[Cause of death and autopsy findings in patients of the Swiss HIV Cohort Study (SHCS)]. Schweiz Med Wochenschr (2000) 0.75
T cell response to staphylococcal superantigens by asymptomatic HIV-infected individuals exhibits selective changes in T cell receptor V beta-chain usage. AIDS Res Hum Retroviruses (1993) 0.75
[The role of T-lymphocytes in organ-specific autoimmune diseases]. Schweiz Med Wochenschr (1987) 0.75
Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection. J Acquir Immune Defic Syndr (2001) 0.75
Kaposi's sarcoma patients in the Swiss HIV Cohort Study with and without detectable human herpesvirus 8 in peripheral blood mononuclear cells. AIDS (1997) 0.75